CF
KDNY

Centaurus Financial’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Centaurus Financial’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-17
Closed -$624 – 556
2018
Q3 		$624 Sell
17
-16,086
-100% -$516K 0.11% 203
2018
Q2 		$564K Buy
+16,103
New +$617K 0.08% 277

Other funds holding KDNY

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Centaurus Financial's KDNY Position: Q4 2018 in Review

Centaurus Financial sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q4 2018, closing a stake of 17 shares — an estimated $624 sold.

Centaurus Financial first reported a position in KDNY in Q2 2018 and held it in 2 quarters. The position peaked at $564K in Q2 2018. 85 funds tracked by Wall St. Rank hold KDNY as of Q4 2018.

  • Centaurus Financial reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • Centaurus Financial sold 17 Chinook Therapeutics, Inc. Common Stock shares in Q4 2018, an estimated $624.
  • Centaurus Financial first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2018 and held it in 2 quarters.
  • Centaurus Financial's Chinook Therapeutics, Inc. Common Stock position peaked at $564K in Q2 2018.
  • 85 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q4 2018.

Based on Centaurus Financial's 13F filing for Q4 2018, filed 12 Feb 2019.